BLRX
BioLineRx Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.64
−1.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4M | 1.2M | 28.9M | 4.8M | — |
| Cost of Revenue | 422.0K | 759.0K | 9.3M | 3.7M | — |
| Gross Profit | 976.3K | 430.4K | 19.7M | 1.1M | — |
| Operating Expenses | |||||
| R&D Expense | 9.7M | 7.7M | 9.1M | 12.5M | 17.6M |
| SG&A Expense | 3.5M | 3.1M | 28.5M | 31.2M | 11.5M |
| General & Admin Expense | 1.7M | — | 18.5M | 16.6M | 5.1M |
| Selling & Marketing Expense | — | — | 10.1M | 14.6M | 6.5M |
| Other Expenses | — | — | 2.4M | 7.1M | — |
| Total Operating Expenses | 13.2M | 10.8M | 40.1M | 50.8M | 29.2M |
| Cost and Expenses | 13.7M | 11.6M | 49.3M | 54.5M | 29.2M |
| Operating Income (EBIT) | (12.3M) | (10.4M) | (20.4M) | (49.7M) | (29.2M) |
| Non-Operating | |||||
| Interest Income | 1.0M | 1.1M | 1.8M | 2.0M | 694.0K |
| Interest Expense | 1.0M | 1.3M | 9.2M | 2.2M | 2.2M |
| Net Interest Income | (23.2K) | (157.2K) | (7.3M) | (162.0K) | (1.5M) |
| Other Non-Op Income/Expense | 2.0M | 8.3M | 11.2M | (10.9M) | 4.2M |
| Non-Operating Income (excl Interest) | (3.6M) | (9.6M) | (20.3M) | 8.8M | (6.4M) |
| EBT (Pre-Tax Income) | (10.2M) | (2.0M) | (9.2M) | (60.6M) | (25.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (8.0M) | (1.2M) | (9.2M) | (60.6M) | (25.0M) |
| Earnings from Cont. Ops | (10.2M) | (2.0M) | (9.2M) | (60.6M) | (25.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.0M) | (1.2M) | (9.2M) | (60.6M) | (25.0M) |
| Per Share | |||||
| Basic EPS | ($1.82) | ($0.29) | ($4.62) | ($37.74) | ($19.32) |
| Diluted EPS | ($1.82) | ($0.29) | ($4.62) | ($37.74) | ($19.32) |
| Revenue Per Share | $0.31 | $0.29 | $14.49 | $2.99 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 4.4M | 4.1M | 2.0M | 1.6M | 1.3M |
| Diluted Shares Outstanding | 4.4M | 4.1M | 2.0M | 1.6M | 1.3M |
| Profitability Metrics | |||||
| EBITDA | (8.3M) | (224.8K) | 3.9M | (57.1M) | (22.1M) |
| D&A | 349.7K | 527.1K | 4.1M | 1.4M | 654.0K |
| EBIT | (8.6M) | (751.9K) | (147.0K) | (58.5M) | (22.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026